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Abstract
Although TNFa is a strong inducer of apoptosis, its cytotoxicity in most normal cells in vitro requires blockade of NFkB
signaling or inhibition of de novo protein synthesis, typically by the addition of cycloheximide. However, several members of
CCN (CYR61/CTGF/NOV) family of extracellular matrix proteins enable TNFa-dependent apoptosis in vitro without inhibiting
NFkBo rde novo protein synthesis, and CCN1 (CYR61) is essential for optimal TNFa cytotoxicity in vivo. Previous studies
showed that CCN1 unmasks the cytotoxicity of TNFa by binding integrins avb5, a6b1, and the cell surface heparan sulfate
proteoglycan syndecan 4 to induce the accumulation of a high level of reactive oxygen species (ROS), leading to a biphasic
activation of JNK necessary for apoptosis. Here we show for the first time that CCN1 interacts with the low density
lipoprotein receptor-related protein 1 (LRP1) in a protein complex, and that binding to LRP1 is critical for CCN1-induced ROS
generation and apoptotic synergism with TNFa. We also found that neutral sphingomyelinase 1 (nSMase1), which
contributes to CCN1-induced ROS generation, is required for CCN1/TNFa-induced apoptosis. Furthermore, CCN1 promotes
the activation of p53 and p38 MAPK, which mediate enhanced cytochrome c release to amplify the cytotoxicity of TNFa.B y
contrast, LRP1, nSMase1, p53, and p38 MAPK are not required when TNFa-dependent apoptosis is facilitated by the
presence of cycloheximide, indicating that they function in the CCN1 signaling pathway that converges with TNFa-induced
signaling events. Since CCN1/CYR61 is a physiological regulator of TNFa cytotoxicity at least in some contexts, these
findings may reveal important mediators of TNFa-induced apoptosis in vivo and identify potential therapeutic targets for
thwarting TNFa-dependent tissue damage.
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Introduction
Apoptosis is an important cellular process in embryonic
development, immune system function, tissue homeostasis, and
tumor suppression. Among the many physiological factors that can
trigger apoptosis is tumor necrosis factor a (TNFa), which plays an
important role in regulating the immune response [1]. TNFa-
induced apoptosis has been implicated in a variety of pathologies
linked to chronic inflammation and auto-immune diseases, most
demonstrably in liver diseases including alcoholic and inflamma-
tory hepatitis [2,3], ischemia/reperfusion liver injury [4], and
fulminant hepatic disease [5].
TNFa-induced apoptosis is mediated through its cell surface
receptor TNFR1 and involves the assembly of two signaling
complexes that sequentially activate NFkB and caspases [6].
Binding of TNFa to TNFR1 triggers receptor trimerization and
the recruitment of TRADD, RIP1 and TRAF2. This receptor-
associated complex promotes the activation of NFkB, a transcrip-
tion factor that induces expression of many pro-inflammatory,
pro-mitogenic, and anti-apoptotic genes [7]. Following TNFR1
endocytosis, TRADD, RIP1 and TRAF2 become modified and
dissociate from the receptor in the cytosol, whereupon they bind to
FADD to recruit and activate caspases-8/10, leading to apoptosis
[6]. However, apoptosis is continuously inhibited by many anti-
apoptotic factors whose expression is induced by NFkB. Among
these are c-FLIP, which binds FADD and inhibit caspases 8/10
activation [8]; MAPK phosphatases, which can dephosphorylate
and inactivate JNK [9]; anti-oxidant proteins such as Mn
++-SOD
and ferritin heavy chain, which inhibit the accumulation of ROS
[10]; as well as caspase inhibitors (XIAP, c-IAP1, cIAP2, survivin)
and anti-apoptotic members of the Bcl family (Bcl-XL, Nr13, and
A1/Bfl1) [7,11]. Therefore, manifestation of TNFa-induced
apoptosis in normal cells in vitro often requires blockade of NFkB
signaling or inhibition of de novo protein synthesis, typically by the
addition of inhibitors of transcription (e.g., actinomycin D) or
protein synthesis such as cycloheximide (CHX) [1].
The ability of TNFa to induce apoptosis in vivo may depend on
regulation by other factors in the tissue microenvironment, and is
therefore context-dependent. Recent studies have shown that
CCN1, CCN2, and CCN3, members of the CCN (CYR61/
CTGF/NOV) family [12] of extracellular matrix (ECM) proteins,
can enable TNFa to induce apoptosis without inhibiting NFkB
signaling or de novo protein synthesis [13], suggesting that the ECM
can profoundly influence the biological response to TNFa.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31303Moreover, knockin mice that express an apoptosis-defective
CCN1 mutant are substantially resistant to TNFa-mediated
apoptosis in vivo, indicating that CCN1 is a physiologic regulator
of TNFa cytotoxicity [14]. These findings suggest that CCN1/
TNFa-induced apoptosis, which may occur through signaling
pathways distinct from one facilitated by the presence of
cycloheximide, may more accurately reflect physiological apoptot-
ic processes in certain biological contexts.
A member of the CCN family of matricellular proteins [12,15],
CCN1 (CYR61) regulates diverse cellular responses including cell
adhesion, migration, proliferation, differentiation, and survival
[16]. Previous studies showed that CCN1 enables TNFa-induced
apoptosis by binding integrins avb5, a6b1, and the cell surface
heparan sulfate proteoglycan (HSPG) syndecan 4 to trigger the
production of reactive oxygen species (ROS) through 5-lipoxy-
genase and mitochondria, leading to the biphasic activation of
JNK critical for apoptosis [14]. Here we have uncovered several
additional essential players in CCN1/TNFa-induced apoptosis.
First, we show for the first time that CCN1 interacts with the low
density lipoprotein receptor-related protein 1 (LRP1) in a protein
complex. This interaction with LRP1 contributes to CCN1-
induced ROS accumulation and CCN1/TNFa-induced apopto-
sis, suggesting that LRP1 is a coreceptor for CCN1 critical for
mediating these processes. Second, we show that neutral
sphingomyelinase 1 (nSMase1), previously shown to participate
in the generation of CCN1-induced ROS [17], also contributes to
TNFa cytotoxicity. Third, we found that p53 and p38 MAPK are
required for facilitating cytochrome c release critical for apoptosis.
By contrast, LRP1, nSMase1, p53, and p38 are not required for
TNFa-induced apoptosis facilitated by CHX. These findings
provide new insights into the signaling pathway for CCN1/TNFa-
mediated apoptosis, which operates in vivo, and underscore
potential targets for intervention in combating TNFa-dependent
tissue damage in certain inflammatory diseases.
Results and Discussion
LRP1 is a CCN1 coreceptor required for CCN1-induced
ROS production and CCN1/TNFa-induced apoptosis
Low density lipoprotein receptor-related protein 1 (LRP1) is a
cell surface endocytic receptor of the low density lipoprotein
receptor family [18]. It consists of an extracellular 515 kDa
subunit that binds more than 30 diverse ligands and a
transmembrane 85 kDa subunit that interacts with several adaptor
proteins to mediate endocytosis and signaling. LRP1 is associated
with and serves as a coreceptor for many growth factor receptors
and integrins, facilitating receptor endocytosis and signaling.
LRP1 binds CCN2 [19], a CCN family member homologous to
CCN1, and is required for CCN2-mediated cell adhesion and
CCN2/TGF-b-induced myofibroblast differentiation [20,21].
However, its interaction with CCN1 has not been assessed
heretofore. In primary human skin fibroblasts (HSFs), we detected
the 515 kDa subunit of LRP1 in the protein complex immuno-
precipitated with anti-CCN1 antibodies (Fig. 1A, lane 3), but not
with isotype control IgG (Fig. 1A, lane7). To establish the
interaction between LRP1 and CCN1 further, we tested the effects
of recombinant receptor-associated protein (RAP), a chaperone of
LRP1 commonly used to inhibit LRP1 ligand binding in vitro
[22,23]. Pre-incubation of cells with 1 mM RAP abolished co-
immunoprecipitation of LRP1 with CCN1 (Fig. 1A, lane 4). These
results indicate that CCN1 physically interacts with LRP1 in a
protein complex.
Since LRP1 functions as a coreceptor with integrins for CCN2
[20,24,25], we tested the possibility that it may also serve as a
coreceptor for CCN1 to mediate apoptosis with TNFa using three
approaches. First, we used siRNA to silence LRP1 expression in
human skin fibroblasts (HSFs), as shown by immunoblot analysis
(Fig. 1B). Strikingly, LRP1 silencing reduced CCN1/TNFa-
induced apoptosis by ,70% compared to control siRNA
(Fig. 1B). In contrast, LRP1 siRNA caused an increase, albeit
not statistically significant, in TNFa-induced apoptosis facilitated
by CHX (Fig. 1B). Second, pre-incubation of HSFs with
recombinant RAP inhibited the apoptotic response to CCN1/
TNFa by ,60%, but did not affect cell sensitivity to CHX/TNFa
(Fig. 1C). Third, pre-treatment of HSFs with the monoclonal
antibody against the LRP1 ectodomain (clone 8G1), but not with
control antibody, abrogated CCN1/TNFa apoptosis without
affecting CHX/TNFa-induced cell death (Fig. 1D). These results
show that LRP1 function is critical for CCN1/TNFa-, but not for
CHX/TNFa-induced cytotoxicity.
We have previously shown that CCN1 binding to integrins avb5
and a6b1, as well as the HSPG syndecan-4, are required for the
generation of a high level of ROS [14]. Inhibition of CCN1-
induced ROS by scavengers, or blockade of ROS-generating
pathways, annihilated apoptotic synergism between CCN1 and
TNFa [14]. Our finding that LRP1 is required for CCN1/TNFa-
induced apoptosis prompted us to test whether it plays a role in
CCN1-induced ROS production. LRP1 siRNA had no effect on
basal ROS level of cells, but reduced CCN1-stimulated ROS
levels for ,50%, as shown by DCF fluorescence (Fig. 2),
suggesting that LRP1 is important for optimal ROS production
upon CCN1 stimulation and this may explain its role in CCN1/
TNFa-induced apoptosis. The partial inhibition of ROS by LRP1
siRNA suggests that CCN1 binding to integrins avb5 and a6b1,
and syndecan-4 may account for the remaining CCN1-induced
ROS generation.
Taken together, these results indicate that LRP1 serves as a
CCN1 coreceptor and contributes to mediating CCN1-induced
ROS accumulation, which is critical for apoptotic synergism with
TNFa. Since LRP1 can promote endocytosis of many receptor-
ligand complexes [26], it is possible that LRP1 is complexed with,
and promotes endocytosis of, integrins avb5 and/or a6b1-HSPG
upon their interaction with CCN1. Since LRP1 is not required for
CHX/TNFa-induced apoptosis (Fig. 1B–D), it appears that LRP1
is not implicated in the internalization of the TNFa receptor 1
(TNFR1), even though TNFR1 internalization is important for
TNFa cytotoxicity [27]. The requirement of multiple CCN1
receptors for CCN1/TNFa-induced apoptosis, including LRP1,
integrins, and syndecan 4, may contribute to the specificity of the
target cells, which must express the correct combination of
receptors for responsiveness. Interestingly, a combination of
CCN1 mutants that are unable to bind either avb5 or a6b1-
HSPG, each defective for apoptosis with TNFa, can fully
reconstitute wild type activity [14]. These results indicate that
CCN1 can bind the integrins separately and signaling through
these receptors converges within the cell to initiate the biological
response.
ROS-dependent p38 MAPK activation is required for
CCN1/TNFa-induced apoptosis
Elevated ROS levels elicit multiple cellular responses, including
the activation of stress response kinases such as p38 MAPK and
JNK. This activation is achieved via two mechanisms: 1, ROS can
activate ASK1, a redox-sensitive kinase upstream of p38 and JNK
[28], and 2, ROS can inactivate MAPK phosphatases by oxidizing
the cysteine residues at their active sites, thus preventing the
dephosphorylation and inactivation of MAPKs [29]. We showed
that CCN1-induced ROS enables a prolonged activation of JNK
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31303Figure 2. LRP1 mediates CCN1-induced ROS production. A. HSFs transfected with 80 nM non-targeting control siRNA or siRNA against LRP1,
were used 72 hrs post-transfection for measurement of CCN1-induced ROS by fluorescence microscopy. Cells were loaded with 10 mM CM-H2DCF-DA
and treated with (2 mg/ml) CCN1 for 15 mins. After nuclear counterstaining with Hoechst 33342 dye, multiple areas of the wells were photographed
(left panel) and green fluorescence (DCF) was quantified as described in materials and methods (right panel: *p,0.05, n=3).
doi:10.1371/journal.pone.0031303.g002
Figure 1. LRP1 is essential for CCN1/TNFa-, but not CHX/TNFa-induced apoptosis. A. Detection of LRP1 protein levels in 15 mg of whole cell
protein lysates (lanes 1, 2, 5, and 6), representing 3% of lysate used for immunoprecipitation with 7 mg/ml rabbit polyclonal anti-CCN1 antibody (lanes
3 and 4) or control IgG (lanes 7 and 8). Where indicated, 1 mM recombinant RAP was added to the medium and incubated with cells for 30 min before
cell lysis. Whole cell protein lysates and immune complexes were resolved on 7.5% SDS-PAGE, immunoblotted, and 515 kDa subunit of LRP1 was
detected with monoclonal anti-LRP1. B. HSFs were transfected with 80 nM non-targeting (ctrl) or LRP1 siRNA, and cell death was induced after 72 hrs
by treatment of cells with CCN1 (2 mg/ml) and TNFa (10 ng/ml) for 5 hrs (left panel; *p,0.01; n=3), or with CHX (1 mg/ml) and TNFa for 16 hrs (right
panel; p=0.13; NS-not significant, n=3). Silencing of LRP1 was validated by immunoblot detection of the 515 kDa LRP1 subunit in control or LRP1
siRNA-treated HSFs. ERK1/2 detection serves as a loading control. C. Apoptosis in serum-starved HSFs was induced as described, in the presence or in
the absence of 1 mM recombinant RAP (left panel: *p,0.01; n=3; right panel: NS-not significant, n=3). D. HSFs were pre-incubated with 50 mg/ml of
isotype control IgG or function-blocking monoclonal antibody against LRP1, 8G1 clone (left panel: *p,0.01; n=3; right panel: NS-not significant,
n=3).
doi:10.1371/journal.pone.0031303.g001
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we tested if CCN1 promotes activation of p38 MAPK in a fashion
similar to JNK. We found that TNFa alone, but not CCN1,
stimulated the activation of both p38 MAPK and JNK by
phosphorylation within 15–30 min., whereas stimulation of cells
with both TNFa and CCN1 induced a second phase of p38
MAPK and JNK activation .4 hrs after stimulation (Fig. 3A).
The second phase activation of p38 MAPK is inhibited by either
NAC or BHA, two different ROS scavengers, but the early phase
activation was unaffected (Fig. 3B), showing that this process is
ROS-dependent. Considering that ROS regulates activity of many
of the redox-sensitive kinases and phosphatases [30], it is unlikely
Figure 3. ROS-dependent activation of p38 MAPK is required for CCN1/TNFa-, but not CHX/TNFa-induced apoptosis. A. Immunoblot
analysis of p38 MAPK (left panel) and JNK activation (right panel) at various times after treatment of cells with CCN1 and/or TNFa. Whole cell lysates
were electrophoresed and probed with antibodies against phospho-p38 MAPK (Thr-180/Tyr-182), phospho-JNK1/2 (Thr183/Tyr185), p38 MAPK, and
JNK. B, Cells were incubated for 30 mins with 10 mM NAC or 5 mM BHA prior to treatment with CCN1 (C) and/or TNFa (T), or BSA (B). Cell lysates
collected at early phase (15 mins) or late phase (4 hrs) after CCN1 and/or TNFa treatment were analyzed for phospho-p38 MAPK (Thr-180/Tyr-182)
and p38 MAPK levels by immunoblot. Numbers under the immunoblots are relative signal intensities as determined by densitometry. C. HSFs were
serum-starved overnight and treated with 0.1% DMSO (ctrl) or 20 mM SB202190 for 30 mins, or were subjected to siRNA-mediated silencing of p38a
expression. Apoptosis was then induced by treatment of cells with CCN1 (2 mg/ml) and/or TNFa (10 ng/ml) for 5 hrs. Where indicated, SB202190 was
added 3 hrs after treatment with CCN1 and TNFa.* p ,0.05; n=3. D, Cells were treated with p38 MAPK inhibitor or siRNA as in C, and apoptosis was
induced with CHX (1 mg/ml) and/or TNFa for 16 hrs (left panel: NS-not significant, n=3). Silencing of p38a expression was confirmed by immunoblot
using antibody against p38 MAPK; b-actin served as control (right panel). E, Cells were treated with CCN1 and/or TNFa for 5 hrs, and cytochrome c
and b-actin in cytosolic extracts were detected by immunoblotting. SB202190 (20 mM) or 0.1% DMSO (ctrl) were incubated with cells 30 min prior to
treatments. Numbers under the immunoblots are relative cytochrome c signal intensities as determined by densitometry.
doi:10.1371/journal.pone.0031303.g003
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demonstrate that ROS inhibitors block not only the second phase
of activation of p38 MAPK (Fig. 3B), but also of JNK [14]. The
role of p38 MAPK in TNFa-induced apoptosis has been
controversial and appears to be cell type- and context-dependent
[31,32]. To test whether p38 MAPK is required when TNFa-
induced apoptosis is enabled by CCN1 or CHX, we used either
the chemical inhibitor SB202190 to block its activity or siRNA to
silence the expression of p38a, the most abundant p38 MAPK
isoform in these cells. Either treatment effectively blocked
apoptosis induced by CCN1 and TNFa (Fig. 3C,D right panel),
but not CHX and TNFa (Fig. 3D). To evaluate the functional
significance of the second phase activation of p38 MAPK in
apoptosis, we added the inhibitor SB202190 3 hours after
CCN1/TNFa treatment, when the early phase activation has
already subsided but the late phase activation has not yet begun
(Fig. 3C). This treatment completely blocked apoptosis, indicating
that the late phase activation of p38 MAPK is essential for
CCN1/TNFa-induced apoptosis. Likewise, the late phase
activation of JNK is also required for CCN1/TNFa-induced cell
death [14].
p38 MAPK can enhance cytochrome c release by promoting
mitochondrial translocation of the pro-apoptotic protein Bax from
the cytosol, or by phosphorylating Bcl2 to decrease its anti-
apoptotic activity [33]. Consistently, we detected a significantly
higher level of cytochrome c release from the mitochondria in cells
co-treated with CCN1 and TNFa, and the effect is diminished in
the presence of the p38 MAPK inhibitor SB202190 (Fig. 3E). In
contrast to the context-dependent role of p38 MAPK, JNK
activation appears necessary for TNFa-induced apoptosis gener-
ally [29]. Pretreatment of HSFs with the JNK inhibitor SP600125
blocked TNFa-induced apoptosis facilitated by either CCN1 or
CHX (Fig. S1).
p53 mediates CCN1/TNFa-induced apoptosis through
late phase activation of JNK and p38 MAPK
p53 is a tumor suppressor that functions to promote cell cycle
arrest, apoptosis, or senescence in response to various cellular
stresses such as DNA damage, hypoxia, or oxidative stress [34].
CCN1 interaction with fibroblasts through integrins and HSPGs
leads to a robust and sustained accumulation of ROS, which
triggers a DNA damage response that includes the activation of
ATM, Chk1, Chk2, and p53 [35]. The activation of p53
downstream of CCN1 prompted us to examine whether p53 is
involved in CCN1/TNFa-induced apoptosis. Treatment of cells
with the p53 inhibitor cyclic pifithrin-a(PFTa) or siRNA-mediated
silencing of p53 completely blocked CCN1/TNFa-induced
apoptosis (Fig. 4A), but CHX/TNFa-induced apoptosis was
unaffected by p53 silencing (Fig. 4B). Moreover, p53 knockdown
blocked cytochrome c release in response to CCN1/TNFa
treatment (Fig. 4C). Thus, p53 is critical for mediating TNFa
cytotoxicity facilitated by CCN1 but not by CHX, and acts
upstream of the mitochondria in this process.
Next, we monitored the phosphorylation of JNK and p38
MAPK after stimulation by TNFa and CCN1 as a function of p53
expression. Silencing of p53 by siRNA had no effect on the early
phase (30 min.) of TNFa-induced JNK and p38 (Fig. 5A), but
inhibited the late phase activation (5 hrs) of JNK and p38 by
CCN1/TNFa (Fig. 5B), although the low level of p38 activity
induced by TNFa alone in the late phase persisted. Similar results
were obtained with p53 inhibition by PFT-a (Fig. 5C). These
observations indicate that p53 mediates CCN1/TNFa-induced
apoptosis at least in part through the activation of JNK and p38
MAPK. Although the late phase phosphorylation of JNK and p38
MAPK is ROS-dependent, p53 is not required for CCN1 to
induce ROS accumulation, as chemical inhibition or siRNA
silencing of p53 did not diminish CCN1-induced ROS (Fig. S2).
These results show that p53 can regulate the activation of p38
MAPK and JNK through an as yet undefined, ROS-independent
mechanism.
In vivo studies have found that TNFa-induced apoptosis may be
p53-dependent [36] or independent [37], possibly as a function of
the cellular and tissue context. CCN1/TNFa-induced apoptosis
can occur without de novo protein synthesis [14], and therefore the
role of p53 does not depend upon its transcriptional induction of
pro-apoptotic genes such as PUMA, Noxa, Bax, AIP-1, Apaf-1
and PERP. In addition to regulating p38 MAPK and JNK
activation (Fig. 5), p53 can promote apoptosis by direct physical
interaction with BH3-only proteins such as Bax/Bak, or with Bcl
family members to displace BH3-only proteins, thus leading to Bax
Figure 4. p53 mediates CCN1/TNFa-, but not CHX/TNFa-
induced apoptosis. A. HSFs were treated with 0.1% DMSO (ctrl) or
100 mM cyclic PFT-a for 30 min, or were subjected to siRNA-mediated
silencing of p53 (confirmed by immunoblot using anti-p53 and b-actin
as a loading control; right panel). Cells were then stimulated to undergo
apoptosis by treatment with CCN1 (2 mg/ml) and/or TNFa (10 ng/ml)
for 5 hrs (*p,0.05, n=3). B. Effect of p53 silencing on apoptosis
induced by CHX (1 mg/ml) and/or TNFa for 16 hrs was quantified (NS-
not significant, n=3). C. Immunoblot detection of cytochrome c in
cytosolic extracts of cells treated for 4 hrs with CCN1 (C) and/or TNFa
(T), or BSA (B), with and without silencing of p53. Numbers under the
immunoblots are relative cytochrome c signal intensities as determined
by densitometry.
doi:10.1371/journal.pone.0031303.g004
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induce this mechanism of apoptosis in cells that are deficient in
p21 and are thus more susceptible to apoptosis [40].
nSMase is required for CCN1/TNFa-, but not CHX/TNFa-
induced apoptosis
CCN1 synergizes with TNFa to trigger apoptosis in part by
inducing ROS generation through 5-lipoxygenase and the
mitochondria [14]. Subsequent studies showed that CCN1 also
induces ROS accumulation through nSMase1 [41]. Indeed,
blockade of nSMase activity with the chemical inhibitor
GW4869 abrogated CCN1-induced ROS accumulation, indicat-
ing that nSMase plays a critical role in this process (Fig. S3). This
requirement of nSMase1 for CCN1-induced ROS prompted us to
test whether nSMase1 is involved in TNFa-induced apoptosis.
Treatment of cells with GW4869 or silencing of nSMase1
expression by siRNA inhibited CCN1/TNFa-induced apoptosis
(Fig. 6A), but did not affect CHX/TNFa-induced apoptosis
(Fig. 6B). Silencing of nSMase1 greatly diminished phosphoryla-
tion of JNK and p38 MAPK, and inhibition of nSMase with
GW4869 efficiently blocked cytochrome c release (Fig. 6C,D).
These results indicate that CCN1-induced nSMase1 activity is
critical for ROS generation, and contributes to the activation of
JNK and p38 MAPK necessary for CCN1/TNFa-induced
apoptosis. Inasmuch as nSMase1 knockout mice show no obvious
phenotype under normal growth conditions [42], it would be of
interest to challenge these mice with inflammatory conditions that
invoke TNFa-induced apoptosis, and assess whether their
responses are impaired.
TNFa dysregulation is critically involved in pathogenesis of a
broad range of chronic and acute inflammatory diseases, and
inhibition of TNFa activity has proven an effective therapeutic
approach for the treatment of rheumatoid arthritis, psoriasis, and
inflammatory bowel disease [43]. Much work has been done to
elucidate the molecular mechanism of TNFa-induced apoptosis,
although many of these studies were performed either in certain
cancer cells carrying mutations that render them responsive to
TNFa-induced apoptosis, or in normal cells with the presence of
sensitizing agents such as CHX [8,44]. Like TNFa, CCN1 is
highly expressed in response to infections and tissue injury,
suggesting that CCN1 can interact with TNFa in many
pathological contexts [16]. Indeed, CCN1 is required for TNFa-
induced apoptosis in concanavalin A-induced hepatitis and in the
skin after direct injection of TNFa, showing CCN1 is a
physiological regulator of TNFa-induced apoptosis [14,45]. Thus,
understanding the CCN1/TNFa apoptotic pathway is likely to
provide new insight into how TNFa may trigger apoptosis and
tissue damage in certain inflammatory diseases.
Upon binding of TNFa to TNFR1, the receptor trimerizes and
recruits TRADD, RIP1 and TRAF2 to form a receptor-associated
protein complex, which eventually dissociates from the receptor
and moves to the cytosol, whereupon it binds to FADD and
recruits and activates caspases-8/10, leading to apoptosis [6].
However, TNFa is also a potent activator of NFkB, which inhibits
TNFa-induced apoptosis by inducing the synthesis of several anti-
apoptotic proteins, including caspase inhibitors, anti-oxidant
proteins, MAPK phosphatases, and anti-apoptotic members of
the Bcl family [8,9,10,7,11]. Without affecting NFkB-activation or
blocking protein synthesis, CCN1 induces a high level of ROS
through nSMase1 [17], 5-LOX, and mitochondria to override the
antioxidant effect of NFkB [14], thereby allowing the accumulated
ROS to inhibit the NFkB-induced MAPK phosphatases [29] and
reactivate JNK and p38 MAPK[14] (Fig. 3A,B). Sustained JNK
activation leads to the degradation of c-FLIP [8], whereas re-
activated p38 MAPK promotes cytochrome c release (Fig. 3E).
As members of the CCN family are emerging as potential
therapeutic targets in diseases associated with chronic inflamma-
tion [12], a detailed understanding of how CCNs synergize with
Figure 5. p53 is required for biphasic activation of JNK and p38
MAPK induced by CCN1 and TNFa. A, HSFs were transfected with
p53 siRNA or control siRNA (50 nM), and treated with BSA (B), CCN1 (C),
TNFa (T), or both (CT) for 30 min. Phosphorylation of JNK (Thr183/
Tyr185) and p38 MAPK (Thr-180/Tyr-182), and expression of p53 were
analyzed by immunoblotting. B, cells were transfected as in A and
phosphorylation of JNK and p38 MAPK was analyzed after 5 hrs of
CCN1/TNFa treatment. C, serum-deprived HSFs were incubated with
100 mM PFT-a for 30 mins and analyzed after 5 hrs of treatment with
proteins as described above.
doi:10.1371/journal.pone.0031303.g005
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Here we have identified four previously unknown essential
participants in the CCN1/TNFa apoptosis pathway: LRP1,
nSMase1, p53 and p38 MAPK (Fig. 7). None of them is necessary
when TNFa cytotoxicity is facilitated by CHX, suggesting that their
functions may counteract the activity of NFkB-induced anti-
apoptotic proteins. These findings indicate that TNFa-induced
apoptosis under physiological conditions may proceed in a manner
distinct from its occurrence in the presence of CHX. Given the
importance of CCN1 in TNFa-induced apoptosis in hepatitis [13],
assessing whether these participants in the CCN1/TNFa apoptosis
pathway play significant roles in TNFa-induced tissue injuries in
inflammatory diseases may help to identify potential targets for
therapeutic intervention [12]. Even though anti-TNFa therapy is
successful in treating several inflammatory diseases, it is often
accompanied by increased bacterial and viral infections [46,47],
and increased risk for the development of lymphomas [48]. Thus,
development of novel therapeutics may be useful in overcoming the
limitations of anti-TNFa therapy. Targeting of LRP1 or nSMase1,
individually or incombination, may selectivelyblock TNFa-mediated
apoptosis while preserving other protective functions of this cytokine.
Inasmuch as p53 and p38 MAPK play important roles in tumor
suppression [49,50], their inactivation may be an inappropriate
therapeutic strategy in some contexts. Therefore, LRP1 and
nSMase1 signaling pathways may be promising therapeutic targets
in treating conditions related to excessive TNFa-induced apoptosis.
Materials and Methods
Cell culture
Data presented in this study were obtained using 1064Sk human
skin fibroblasts (HSFs) derived from skin biopsies of a healthy
newborn (American Type Culture Collection CRL-2076). We also
tested three other primary neonatal fibroblast isolates (BJ, 1077 Sk,
HFF-1)forapoptoticsynergybetweenCCN1and TNFa,andfound
that they all responded similarly. Fibroblasts were maintained in the
Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen) with
10% fetal bovine serum (FBS, Hyclone) at 37uC and 5% CO2,a n d
used before reaching 25 population doublings. Before experiments,
cells were serum-deprived by overnight incubation in IMDM
containing 0.1% bovine serum albumin (BSA).
Antibodies and reagents
Human recombinant TNFa was from Axxora. Antibodies for
phospho-p38 MAPK (Thr-180/Tyr-182), c-Jun N-terminal pro-
tein kinase 1/2 (JNK1/2), and ERK1/2 were from Cell Signaling
Technology, for phospho-JNK1/2 (Thr183/Tyr185) from Assay
Designs, for p38 MAPK and p53 (DO-1) from Santa Cruz
Biotechnology, for cytochrome c from Clontech, and antibody
against 515 kDa subunit of LRP1 (8G1) was from Fitzgerald
Industries. Anti-b-actin antibody (AC-15), CHX, NAC, BHA, and
neutral sphingomyelinase inhibitor GW4869 were from Sigma.
Inhibitors of p38 MAPK (SB202190), JNK (SP600125), and p53
Figure 6. nSMase mediates CCN1/TNFa-, but not CHX/TNFa-induced apoptosis. A, HSFs were either treated with 0.1% DMSO (ctrl) or 20 mM
GW4869 for 30 mins, or subjected to siRNA-mediated silencing of nSMase1 (SMPD2). Cells were then tested for apoptosis in response to CCN1 (2 mg/
ml) and/or TNFa (10 ng/ml). (*p,0.05; n=3). On the right is RT-PCR analysis of SMPD2 and GAPDH expression in cells transfected with control or
SMPD2 siRNA. B. Apoptotic response of cells to CHX (1 mg/ml) and/or TNFa was assessed after the inhibition of nSMase with GW4869, or upon siRNA-
mediated silencing of nSMase1 (NS-not significant, n=3). C, HSFs were transfected with control siRNA or siRNA against nSMase 1, and stimulated for
5 hrs with BSA (B), CCN1 (C), TNFa (T), or both (CT). Phosphorylation of JNK (Thr183/Tyr185) and p38 MAPK (Thr-180/Tyr-182) was analyzed by
immunoblotting. Numbers under the immunoblots are relative signal intensities as determined by densitometry. D, HSFs were incubated with
GW4869 (20 mM) where indicated, and treated with CCN1 and/or TNFa for 5 hrs. Cytosolic extracts were electrophoresed and cytochrome c was
detected by immunoblotting. Numbers under the immunoblots are relative cytochrome c signal intensities as determined by densitometry.
doi:10.1371/journal.pone.0031303.g006
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detection dyes 5-(and 6-) chloromethyl-29,79-dichlorodihydrofluor-
escein diacetate (CM-H2DCF-DA) and dihydrocalcein acetoxy-
methylester (DHC-AM) were from Invitrogen.
Coimmunoprecipitation of LRP1 and CCN1
HSFs were rinsed twice with ice-cold PBS and lysed in
immunoprecipitation (IP) buffer (20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% Triton X-100,
and EDTA-free protease inhibitor cocktail). After 5 min of
incubation at 37uC, cell lysates were passed through a 22-gauge
needle 10 times and cleared by centrifugation at 14,0006ga t4 uC
for 20 min. Protein concentration in supernatants was adjusted to
1 mg/ml and 0.5 ml of the lysate was combined with 3.5 mgo f
CCN1 antibody or control purified normal rabbit IgG. After
overnight incubation at 4uC, lysate-antibody mixture was
combined with 50 ml of 25% slurry Protein A/G PLUS-Agarose
(Santa Cruz Biotechnology) and incubated for another 4 hrs at
4uC. The beads were then washed once with IP buffer and twice
with 0.1% Triton X-100-containing IP buffer. Bead pellets were
combined with 40 ml of 2X non-reducing sodium dodecyl sulfate
(SDS) buffer and boiled for 5 min. After centrifugation, the
supernatants were separated by 7.5% SDS-PAGE and LRP1
expression was analyzed by Western blotting.
Expression and purification of recombinant CCN1 and
RAP
Human recombinant CCN1 protein was produced in insect
cells using a baculovirus expression system [51] GST-RAP fusion
protein was expressed in BL21 E.coli transformed with pGEX-2T-
RAP/TEV (kindly provided by Dr. Klavs Dolmer, University of
Illinois at Chicago). RAP was purified as described before [52].
First, GST-RAP was affinity-purified using glutathione sepharose
4B (GE Healthcare). GST-RAP was then digested by overnight
incubation with TEV protease (Promega) and the GST tag was
removed on GSH-Sepharose. Purity of the recombinant proteins
was verified by Commassie staining after SDS-PAGE.
Apoptosis assays
HSFs were incubated in serum-free medium overnight then
treated with recombinant proteins and/or inhibitors to induce
apoptosis. Cells were fixed with 10% formalin and stained with
DAPI (49,6-diamidino-2-phenylindole, 1 mg/ml). Apoptotic cells
were counted under a fluorescent microscope in 10 randomly
Figure 7. TNFa-induced apoptotic signaling. TNFa acts via its death domain containing receptor TNFR1 to activate caspase 8/10 and promote
apoptosis signaling. However, TNFa also activates NFkB to induce expression of a variety of anti-apoptotic genes, resulting in blockade of TNFa-
induced apoptosis. The extracellular matrix protein CCN1 unleashes TNFa apoptosis signaling without inhibiting NFkB. Instead, CCN1 acts via
integrins avb5 and a6b1, syndecan-4, and LRP1 to induce a high level of ROS in cells, overriding the anti-oxidant effects of NFkB. CCN1-induced ROS,
generated via mitochondria, 5-LOX, and nSMase-dependent mechanism, causes a prolonged activation of stress-activated kinases p38 MAPK and
JNK. This hyperactivation of kinases depends on p53, which is activated downstream of ROS. JNK enables caspase activation by TNFa by inducing the
degradation of caspase inhibitor cFLIP via ubiquitin ligase Itch. In contrast, CCN1-mediated activation p38 MAPK promotes cytochrome c release to
facilitate TNFa-mediated apoptosis at the level of mitochondria. In contrast to CCN1, CHX triggers TNFa-mediated apoptosis by blocking de novo
protein synthesis, including the synthesis of NFkB targets, such as anti-oxidant proteins and protein kinase phosphatases. This results in accumulation
of ROS, activation of JNK, and apoptosis, without the requirement of p38 MAPK or p53.
doi:10.1371/journal.pone.0031303.g007
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are presented as mean % apoptosis 6 standard deviation (SD)
from triplicate samples. All apoptosis assays were done at least
three times with similar results.
Immunobloting
Cell lysates were made in RIPA buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% (w/v) NP-40, 0.5% sodium
deoxycholate, and 0.1% SDS) and were diluted in Laemmli
buffer prior to SDS-PAGE. LRP1 was detected under non-
reducing conditions, after combining cell lysates with 2X non-
reducing SDS buffer (125 mM Tris-HCl pH 6.8, 2.5% SDS, 25%
glycerol and 2 mg/ml N-ethylmaleimide). Immunoblotting and
protein detection were done using standard methods. X-ray
images were scanned and relative band intensity was measured
using ImageJ 1.36b software (NIH).
Cytochrome c release from mitochondria
Cytosolic extracts free of mitochondria were prepared as
described [53]. Briefly, cells were harvested by trypsinization
and lysed for 10 min at 25uC in 0.5 ml of mannitol/sucrose buffer
(20 mM HEPES-KOH, (pH 7.5), 210 mM sucrose, 70 mM
mannitol, 1.5 mM MgCl2, 10 mM KCl2, EDTA-free protease
inhibitor cocktail (Roche), and 20 mg digitonin/million cells). After
centrifugation at 14,0006g, supernatants representing cytosolic
fractions, containing 50 mg of protein, were analyzed for the
presence of cytochrome c and b-actin by immunoblot.
ROS measurements
Reactiveoxygenspeciesinlivecellsweredetectedbyfluorescence
microscopy (Leica, DMIRB), usingcell-permeableindicatordyes 5-
(and 6-) chloromethyl-29,79-dichlorodihydrofluorescein diacetate
(CM-H2DCF-DA) [54] or DHC-AM [55]. The reduced and
acetylated indicator dyes are non-fluorescent, but removal of the
acetate groups by cellular esterases and oxidation by peroxides,
convert them into green-fluorescent products reflecting the amount
of ROS. Cells were loaded with 10 mM ROS indicator dye and
treated with CCN1 for 10 mins. After counterstaining with Hoechst
33342, five random high-power fields of each sample were
photographed using QImaging Retiga 2000R camera. Green
fluorescence intensities were measured with ImageJ 1.36b software
(NIH) and expressed as fluorescence intensity per cell. For
measurement of ROS by flow cytometry (supplementary data),
serum-deprived cells were labeled with CM-H2DCF-DA (5 mM) for
15 mins at 37uC in the dark, and stimulated for 10 mins with
recombinant CCN1. After rinsing and detachment with trypsin/
EDTA, cells were suspended in 5% FBS-containing PBS at the
concentration of 2610
5 cells/ml. Fluorescence of 10
5 cells was
immediately analyzed by flow cytometry (Cell Lab Quanta SC
MPL; Beckman Coulter). Data were expressed as geometric mean
fluorescence 6 SD from triplicate samples.
siRNA
Cells were transfected with siRNAs using Lipofectamine 2000
reagent (Invitrogen) according to manufacturer’s protocol, and
assayed for apoptosis or ROS 72 hrs after transfection. Control
non-targeting siRNA and siGENOME SMARTpool siRNA
against nSMase1 (50 nM) were from Dharmacon. siRNAs against
LRP1 (sense: GCAGUUUGCCUGCAGAGAU-dTdT) [56],
p38a (sense: CCUACAGAGAACUGCGGUU-dTdT) [57], and
p53 (sense: GACUCCAGUGGUAAUCUAC-dTdT) [58] were
from Ambion. The silencing was validated using RT-PCR in case
of nSMase1 siRNA treatment, or by immunoblot in case of LRP1,
p38, and p53 siRNAs.
Semiquantitative RT-PCR
Total cellular RNA was extracted and cDNA synthesized using
standard methods. PCR primers specific for nSMase1 (forward,
59-CAACAAGTGTAACGACGATGCC-39; reverse, 59-CGAT-
TCTTTGGTCCTGAGGTGT-39) and GAPDH (forward, 59-A-
TCGTGGAAGGACTCATGACCACA-39; reverse, 59-CCTGC-
TTCACCACCTTCTTGATGT-39) were used.
Statistical analysis
Data are reported as the mean 6 SD, and analyzed using
Student’s t-test. p values#0.05 were considered significant.
Supporting Information
Figure S1 JNK is required for TNFa cytotoxicity in-
duced both by CCN1 and CHX. A, serum-deprived HSFs
were treated with 0.1% DMSO (ctrl) or 15 mM SP600125 for
30 mins prior to apoptosis induction with CCN1 (2 mg/ml) and/or
TNFa (10 ng/ml) for 5 hrs, and apoptosis was assayed. B, cells
were prepared as in A but apoptosis was induced with CHX (1 mg/
ml) and or TNFa (10 ng/ml) for 16 hrs; *p,0.05; n=3.
(TIF)
Figure S2 p53 is not required for CCN1-induced ROS
accumulation. A, HSFs were incubated with 0.1% DMSO (ctrl)
or 10 mM PFTm for 30 mins before loading with 5 mM CM-
DCFDA. Cells were then treated either with BSA or CCN1 (2 mg/
ml) and harvested after 10 mins for measurement of ROS by flow
cytometry. B, HSFs were transfected with p53 siRNA, or control
siRNA, and ROS was detected as above. Results are expressed as
geometric mean fluorescence 6 SD. *p,0.01; n=3.
(TIF)
Figure S3 nSMase1 is required for CCN1-induced ROS
accumulation. Serum-deprived HSFs were loaded with 10 mM
DHC-AM and treated with CCN1 for 15 mins. After nuclear
counterstaining with DAPI, cells were photographed (left). Green
fluorescence (DHC-AM) was quantified (right panel) to reflect ROS
levels.
(TIF)
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